Ankit Mahadevia
Overview
Ankit Mahadevia received an average of $3M in total compensation, including $496K in salary, at Spero Therapeutics from 2016 to 2022.
2022Spero TherapeuticsFormer President and Chief Executive Officer
2021Spero TherapeuticsChief Executive Officer
2020Spero TherapeuticsChief Executive Officer
2019Spero TherapeuticsChief Executive Officer
2018Spero TherapeuticsChief Executive Officer
2017Spero TherapeuticsChief Executive Officer
2016Spero TherapeuticsChief Executive Officer
Source: SEC filings on September 1, 2023, August 5, 2022, September 30, 2020, April 26, 2019, and April 27, 2018.
Related executives
We found six more executives who work or worked at Spero Therapeutics.
Satyavrat Shukla
Spero Therapeutics
Chief Executive Officer
Tamara Joseph
Spero Therapeutics
Chief Legal Officer
Cristina Larkin
Spero Therapeutics
Chief Operating Officer
Christina Larkin
Spero Therapeutics
Chief Operating Officer
David Melnick
Spero Therapeutics
Chief Medical Officer
Joel Sendek
Spero Therapeutics
Chief Financial Officer
News
Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
September 1, 2023
Spero Therapeutics CEO Ankit Mahadevia's 2021 pay jumps 130% to $4.9M
August 5, 2022
Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M
September 30, 2020
Spero Therapeutics Chief Medical Officer David Melnick receives $1.6M in 2018
April 26, 2019